Recordati Industria Chimica e Farmaceutica S.p.A. (FRA:RER1)

Market Cap	10.00B -7.2%
Revenue (ttm)	2.62B +11.8%
Net Income	443.62M +6.5%
EPS	2.12 +6.5%
Shares Out	n/a
PE Ratio	22.54
Forward PE	14.93
Dividend	1.34 (2.76%)
Ex-Dividend Date	May 18, 2026

Volume	n/a
Average Volume	55
Open	48.06
Previous Close	45.86
Day's Range	48.06 - 49.34
52-Week Range	43.42 - 55.35
Beta	n/a
RSI	63.21
Earnings Date	Mar 19, 2026

About FRA:RER1

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing’s syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due ...

• Industry: Pharmaceutical Preparations
• Founded: 1926
• Employees: 4,450
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RER1

Financial Performance

In 2025, FRA:RER1's revenue was 2.62 billion, an increase of 11.82% compared to the previous year's 2.34 billion. Earnings were 443.62 million, an increase of 6.51%.